论文部分内容阅读
目的:研究神经节苷脂GM1治疗新生儿缺氧缺血性脑病(HIE)血液中NO、NOS和ET-1的变化。方法:将30例HIE新生儿分为GM1和其他药物治疗组,另有1组10例作为正常对照组。两HIE组常规治疗3d后分别用GM1和其他药物治疗不少于10d。测定生后第3天和第14天血清中NO、NOS和血浆ET-1水平。结果:两治疗组治疗后NO,NOS,ET-1均显著降低,与正常组无显著性差异;GM1治疗组NO和NOS降低与对照组有显著性差异,但ET-1没有显著性差异。结论:GM1治疗HIE可以降低血中NO、NOS和ET-1,减轻其有害作用,改善脑的供血异常,减轻脑损害,其作用优于其他药物。
AIM: To investigate the changes of NO, NOS and ET-1 in the blood of ganglioside GM1 in neonates with hypoxic-ischemic encephalopathy (HIE). Methods: Thirty neonates with HIE were divided into GM1 and other drug treatment groups, and another group of 10 as normal control group. Two HIE group after conventional treatment with GM1 and other drugs were treated for not less than 10d. Serum levels of NO, NOS and plasma ET-1 were measured at 3 and 14 days after birth. Results: The levels of NO, NOS and ET-1 in the two treatment groups were significantly lower than those in the normal control group. The NO and NOS in the GM1 treatment group were significantly lower than those in the control group, but ET-1 had no significant difference. Conclusion: GM1 treatment of HIE can reduce blood NO, NOS and ET-1, reduce its harmful effects, improve brain blood supply abnormalities, reduce brain damage, its effect is superior to other drugs.